Top

Cancer Cell International

Published in:

Open Access 01-12-2021 | osteosarcoma | Primary research

Recognize the role of CD146/MCAM in the osteosarcoma progression: an in vitro study

Authors: Xing Lei, Kewei Wang, Wenbo Wang, Hao Jin, Wenguang Gu, Zhiguo Chen, Wei Wang, Kaituo Gao, Huan Wang

Published in: Cancer Cell International | Issue 1/2021

Abstract

Background

Osteosarcoma (OS) is a common malignant bone tumor with poor prognosis. We previously reviewed that CD146 is correlated with multiple cancer progression, while its impact on OS is currently not systematically studied.

Methods

MG63 was transfected with lentivirus to express CD146 ectopically, and anti-CD146 neutralizing antibody ab75769 was used to inhibit 143B. Cyclic migration of MG63 and co-culture between MG63 and 143B were used to explore the role of OS malignancy in CD146 expression. The effect of OS cell medium (CM) on endothelium behaviors was assessed, and the expression changes of CD146 before and after co-culture of endothelium and OS were evaluated. Finally, the expression of CD146 in OS was detected under different culture conditions, including hyperoxia, low oxygen, high glucose and low glucose conditions.

Results

CD146 promoted the colony formation, migration, invasion and homotypic adhesion of OS cells, and reducing the concentration of soluble CD146 in the OS medium inhibited the proliferation, migration and lumen formation of the cultured endothelium. However, CD146 did not affect the adhesion between OS and endothelium, nor did co-culture of both sides affect the CD146 expression. Similarly, the proliferation, migration and CD146 expression of MG63 remained unchanged after many cycles of migration itself, as did its co-culture with 143B for expressing CD146. In addition, we also showed that high glucose promoted the expression of CD146 in OS, while hypoxia had the opposite effect.

Conclusions

These findings demonstrate that CD146 promotes OS progression by mediating pro-tumoral and angiogenic effects. Thus, CD146 could be a potential therapeutic target for OS, especially for OS patients with diabetes.

Available only for authorised users

Pingping B, Yuhong Z, Weiqi L, et al. Incidence and mortality of sarcomas in Shanghai, China, During 2002–2014. Front Oncol. 2019;9:662. https://doi.org/10.3389/fonc.2019.00662.CrossRefPubMedPubMedCentral

Lancia C, Anninga JK, Sydes MR, et al. A novel method to address the association between received dose intensity and survival outcome: benefits of approaching treatment intensification at a more individualised level in a trial of the European Osteosarcoma Intergroup. Cancer Chemother Pharmacol. 2019;83:951–62. https://doi.org/10.1007/s00280-019-03797-3.CrossRefPubMedPubMedCentral

Berner K, Johannesen TB, Berner A, et al. Time-trends on incidence and survival in a nationwide and unselected cohort of patients with skeletal osteosarcoma. Acta Oncol. 2015;54:25–33. https://doi.org/10.3109/0284186X.2014.923934.CrossRefPubMed

Leroyer AS, Blin MG, Bachelier R, et al. CD146 (cluster of differentiation 146). Arterioscler Thromb Vasc Biol. 2019;39:1026–33. https://doi.org/10.1161/ATVBAHA.119.312653.CrossRefPubMed

Wang Z, Xu Q, Zhang N, et al. CD146, from a melanoma cell adhesion molecule to a signaling receptor. Signal Transduct Target Ther. 2020;5:148. https://doi.org/10.1038/s41392-020-00259-8.CrossRefPubMedPubMedCentral

Lei X, Guan CW, Song Y, Wang H. The multifaceted role of CD146/MCAM in the promotion of melanoma progression. Cancer Cell Int. 2015;15:3. https://doi.org/10.1186/s12935-014-0147-z.CrossRefPubMedPubMedCentral

McGary EC, Heimberger A, Mills L, et al. A fully human antimelanoma cellular adhesion molecule/MUC18 antibody inhibits spontaneous pulmonary metastasis of osteosarcoma cells in vivo. Clin Cancer Res. 2003;9:6560–6.PubMed

Chen J, Luo Y, Hui H, et al. CD146 coordinates brain endothelial cell-pericyte communication for blood–brain barrier development. Proc Natl Acad Sci USA. 2017;114:E7622–31. https://doi.org/10.1073/pnas.1710848114.CrossRefPubMed

Zeng Q, Wu Z, Duan H, et al. Impaired tumor angiogenesis and VEGF-induced pathway in endothelial CD146 knockout mice. Protein Cell. 2014;5:445–56. https://doi.org/10.1007/s13238-014-0047-y.CrossRefPubMedPubMedCentral

10.

Guezguez B, Vigneron P, Lamerant N, et al. Dual role of melanoma cell adhesion molecule (MCAM)/CD146 in lymphocyte endothelium interaction: MCAM/CD146 promotes rolling via microvilli induction in lymphocyte and is an endothelial adhesion receptor. J Immunol. 2007;179:6673–85. https://doi.org/10.4049/jimmunol.179.10.6673.CrossRefPubMed

11.

Wellbrock J, Fiedler W. CD146: a new partner for VEGFR2. Blood. 2012;120:2164–5. https://doi.org/10.1182/blood-2012-07-439646.CrossRefPubMed

12.

Flores-Nascimento MC, Alessio AM, de Andrade Orsi FL, Annichino-Bizzacchi JM. CD144, CD146 and VEGFR-2 properly identify circulating endothelial cell. Rev Bras Hematol Hemoter. 2015;37:98–102. https://doi.org/10.1016/j.bjhh.2014.11.014.CrossRefPubMedPubMedCentral

13.

Tu T, Zhang C, Yan H, et al. CD146 acts as a novel receptor for netrin-1 in promoting angiogenesis and vascular development. Cell Res. 2015;25:275–87. https://doi.org/10.1038/cr.2015.15.CrossRefPubMedPubMedCentral

14.

Kaspi E, Guillet B, Piercecchi-Marti MD, et al. Identification of soluble CD146 as a regulator of trophoblast migration: potential role in placental vascular development. Angiogenesis. 2013;16:329–42. https://doi.org/10.1007/s10456-012-9317-6.CrossRefPubMed

15.

Bardin N, Moal V, Anfosso F, et al. Soluble CD146, a novel endothelial marker, is increased in physiopathological settings linked to endothelial junctional alteration. Thromb Haemost. 2003;90:915–20. https://doi.org/10.1267/THRO03050915.CrossRefPubMed

16.

Stalin J, Harhouri K, Hubert L, et al. Soluble melanoma cell adhesion molecule (sMCAM/sCD146) promotes angiogenic effects on endothelial progenitor cells through angiomotin. J Biol Chem. 2013;288:8991–9000. https://doi.org/10.1074/jbc.M112.446518.CrossRefPubMedPubMedCentral

17.

Ostergaard L, Tietze A, Nielsen T, et al. The relationship between tumor blood flow, angiogenesis, tumor hypoxia, and aerobic glycolysis. Can Res. 2013;73:5618–24. https://doi.org/10.1158/0008-5472.CAN-13-0964.CrossRef

18.

Zeng W, Liu P, Pan W, Singh SR, Wei Y. Hypoxia and hypoxia inducible factors in tumor metabolism. Cancer Lett. 2015;356:263–7. https://doi.org/10.1016/j.canlet.2014.01.032.CrossRefPubMed

19.

Liu X, Hemminki K, Forsti A, et al. Cancer risk in patients with type 2 diabetes mellitus and their relatives. Int J Cancer. 2015;137:903–10. https://doi.org/10.1002/ijc.29440.CrossRefPubMed

20.

Garcia-Jimenez C, Gutierrez-Salmeron M, Chocarro-Calvo A, et al. From obesity to diabetes and cancer: epidemiological links and role of therapies. Br J Cancer. 2016;114:716–22. https://doi.org/10.1038/bjc.2016.37.CrossRefPubMedPubMedCentral

21.

Chiang YH, Wu SH, Kuo YC, et al. Raman spectroscopy for grading of live osteosarcoma cells. Stem Cell Res Ther. 2015;6:81. https://doi.org/10.1186/s13287-015-0074-5.CrossRefPubMedPubMedCentral

22.

Schiano C, Grimaldi V, Casamassimi A, et al. Different expression of CD146 in human normal and osteosarcoma cell lines. Med Oncol. 2012;29:2998–3002. https://doi.org/10.1007/s12032-012-0158-3.CrossRefPubMed

23.

Kuijjer ML, Hogendoorn PC, Cleton-Jansen AM. Genome-wide analyses on high-grade osteosarcoma: making sense of a genomically most unstable tumor. Int J Cancer. 2013;133:2512–21. https://doi.org/10.1002/ijc.28124.CrossRefPubMed

24.

Stopp S, Bornhauser M, Ugarte F, et al. Expression of the melanoma cell adhesion molecule in human mesenchymal stromal cells regulates proliferation, differentiation, and maintenance of hematopoietic stem and progenitor cells. Haematologica. 2013;98:505–13. https://doi.org/10.3324/haematol.2012.065201.CrossRefPubMedPubMedCentral

25.

Kolb AD, Bussard KM. The Bone Extracellular Matrix as an Ideal Milieu for Cancer Cell Metastases. Cancers. 2019;11:1020. https://doi.org/10.3390/cancers11071020.CrossRefPubMedCentral

26.

Zeng GF, Cai SX, Wu GJ. Up-regulation of METCAM/MUC18 promotes motility, invasion, and tumorigenesis of human breast cancer cells. BMC Cancer. 2011;11:113. https://doi.org/10.1186/1471-2407-11-113.CrossRefPubMedPubMedCentral

27.

Stalin J, Nollet M, Garigue P, et al. Targeting soluble CD146 with a neutralizing antibody inhibits vascularization, growth and survival of CD146-positive tumors. Oncogene. 2016;35:5489–500. https://doi.org/10.1038/onc.2016.83.CrossRefPubMed

28.

Rapanotti MC, Ricozzi I, Campione E, Orlandi A, Bianchi L. Blood MUC-18/MCAM expression in patients with melanoma: a suitable marker of poor outcome. Br J Dermatol. 2013;169:221–2. https://doi.org/10.1111/bjd.12295.CrossRefPubMed

29.

Pong YH, Su YR, Lo HW, et al. METCAM/MUC18 is a new early diagnostic biomarker for the malignant potential of prostate cancer: validation with Western blot method, enzyme-linked immunosorbent assay and lateral flow immunoassay. Cancer Biomarkers Sect A Dis Markers. 2020;27:377–87. https://doi.org/10.3233/CBM-191001.CrossRef

30.

de Kruijff IE, Timmermans AM, den Bakker MA, et al. The prevalence of CD146 expression in breast cancer subtypes and its relation to outcome. Cancers. 2018;10:134. https://doi.org/10.3390/cancers10050134.CrossRefPubMedCentral

31.

Ouhtit A, Abdraboh ME, Hollenbach AD, Zayed H, Raj MHG. CD146, a novel target of CD44-signaling, suppresses breast tumor cell invasion. Cell Commun Signal. 2017;15:45. https://doi.org/10.1186/s12964-017-0200-3.CrossRefPubMedPubMedCentral

32.

Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 2018;15:81–94. https://doi.org/10.1038/nrclinonc.2017.166.CrossRef

33.

Zhou Y, Yang D, Yang Q, et al. Single-cell RNA landscape of intratumoral heterogeneity and immunosuppressive microenvironment in advanced osteosarcoma. Nat Commun. 2020;11:6322. https://doi.org/10.1038/s41467-020-20059-6.CrossRefPubMedPubMedCentral

34.

Heim X, Joshkon A, Bermudez J, et al. CD146/sCD146 in the pathogenesis and monitoring of angiogenic and inflammatory diseases. Biomedicines. 2020;8:592. https://doi.org/10.3390/biomedicines8120592.CrossRefPubMedCentral

35.

Chen J, Luo Y, Huang H, et al. CD146 is essential for PDGFRbeta-induced pericyte recruitment. Protein Cell. 2018;9:743–7. https://doi.org/10.1007/s13238-017-0484-5.CrossRefPubMed

36.

Infante T, Cesario E, Gallo M, et al. Ex vivo behaviour of human bone tumor endothelial cells. Cancers. 2013;5:404–17. https://doi.org/10.3390/cancers5020404.CrossRefPubMedPubMedCentral

37.

Tormin A, Li O, Brune JC, et al. CD146 expression on primary nonhematopoietic bone marrow stem cells is correlated with in situ localization. Blood. 2011;117:5067–77. https://doi.org/10.1182/blood-2010-08-304287.CrossRefPubMedPubMedCentral

38.

Park KS, Kang SN, Kim DH, et al. Late endothelial progenitor cell-capture stents with CD146 antibody and nanostructure reduce in-stent restenosis and thrombosis. Acta Biomater. 2020;111:91–101. https://doi.org/10.1016/j.actbio.2020.05.011.CrossRefPubMed

Title: Recognize the role of CD146/MCAM in the osteosarcoma progression: an in vitro study
Authors: Xing Lei
Kewei Wang
Wenbo Wang
Hao Jin
Wenguang Gu
Zhiguo Chen
Wei Wang
Kaituo Gao
Huan Wang
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: osteosarcoma
Osteosarcoma
Published in: Cancer Cell International / Issue 1/2021
Electronic ISSN: 1475-2867
DOI: https://doi.org/10.1186/s12935-021-02006-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Echinacoside exerts anti-tumor activity via the miR-503-3p/TGF-β1/Smad aixs in liver cancer

Clinical M2 macrophages-related genes to aid therapy in pancreatic ductal adenocarcinoma

LINC01605, regulated by the EP300-SMYD2 complex, potentiates the binding between METTL3 and SPTBN2 in colorectal cancer

LncRNA ACTA2-AS1 suppress colon adenocarcinoma progression by sponging miR-4428 upregulation BCL2L11

CDC42EP3 promotes colorectal cancer through regulating cell proliferation, cell apoptosis and cell migration

YWHAE as an HE4 interacting protein can influence the malignant behaviour of ovarian cancer by regulating the PI3K/AKT and MAPK pathways

Keynote webinar | Spotlight on antibody–drug conjugates in cancer